CTX-009 + Paclitaxel
Phase 2/3Active 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Biliary Tract Cancer
Conditions
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
Trial Timeline
Jan 9, 2023 → Dec 1, 2025
NCT ID
NCT05506943About CTX-009 + Paclitaxel
CTX-009 + Paclitaxel is a phase 2/3 stage product being developed by Compass Therapeutics for Biliary Tract Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05506943. Target conditions include Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05506943 | Phase 2/3 | Active |
Competing Products
20 competing products in Biliary Tract Cancer